As of Nov 18, 2026, 2 of 2 active firms rate BOLT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BOLT EPS & revenue forecast
EPS · NEXT QUARTER
$-3.85
Range $-4.74 – $-2.96 · 2 analysts · +29% YoY
Next period, 2 analysts expect Bolt Biotherapeutics to earn $-3.85 a share (range $-4.74 – $-2.96), versus $-2.98 a year earlier. Full-year consensus is $-26.29, growing to $-20.19 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $0, rising to $3.5M next year.
Top analysts covering Bolt Biotherapeutics
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BOLT.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$7.00+23.5% to target
Overall win rate
42%
+ Follow
#2
EW
Edward White
HC Wainwright & Co. · Rank #376
Neutral
No targeton BOLT
Overall win rate
31%
+ Follow
#3
Daina Graybosch
Leerink Partners · Rank #396
Neutral
$6.00+5.8% to target
Overall win rate
41%
+ Follow
#4
SW
Stephen Willey
Stifel · Rank #474
Neutral
$1.00-82.4% to target
Overall win rate
29%
+ Follow
#5
CM
Chad Messer
Lake Street
Buy
$75.00+1222.8% to target
Coverage
—
+ Follow
BOLT stock forecast FAQ
What is BOLT's average 12-month price target?+
The 2 active firms with a live target average $14.50 for Bolt Biotherapeutics over the next 12 months, ranging from a $22.00 high to a $7.00 low, as of Nov 18, 2026.
Is BOLT stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 18, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BOLT?+
The Street-high target is $22.00 (Rodman & Renshaw), and the Street-low is $7.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $14.50.
How many active Wall Street firms cover BOLT?+
2 active firms have a recognized rating on Bolt Biotherapeutics as of Nov 18, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BOLT?+
Among analysts who currently cover BOLT, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Buy with a $7.00 target.
What is Bolt Biotherapeutics's projected EPS for next quarter?+
The consensus estimate is $-3.85 per share (range $-4.74 – $-2.96) across 2 analysts. Full-year EPS is projected at $-26.29, rising to $-20.19 the following year.
How much revenue is Bolt Biotherapeutics expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $3.5M next year.
Have analysts been upgrading or downgrading BOLT lately?+
As of Nov 18, 2026, 2 of 2 active firms rate BOLT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BOLT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.